Participants
anaemia, chronic kidney disease, Diabetes
ANAEMIA, RECRUITMENT, CANCER, TYPE 1 DIABETES, DIABETES, TYPE 2 DIABETES, ASYMPTOMATIC HYPOGLYCAEMIA
Recruitment was carried out among subjects presenting on scheduled ambulatory visits for type 2 diabetes at the Diabetes Center of the Békés County Central Hospital in Békéscsaba, Hungary. Outpatients with type 2 diabetes aged ≥ 18 years were enrolled. Main inclusion criteria were as follows: random, non‐fasting serum C‐peptide level ≥1.1 ng/ml (normal range 1.1–4.1 ng/ml), HbA1c ≤ 7.5% (58 mmol/mol), MDI treatment (stable daily doses of insulin at least for 90 days prior to baseline visit [BV] ± metformin), relatively low TDD. At BV, low TDD was defined as TDD ≤70 IU/day and TDD ≤0.6 IU/kg/day at the same time. Patients reporting severe or repeated symptomatic hypoglycaemia during the month before BV using TDD ≤70 IU/day and >0.6 but <0.8 IU/kg/day could also be recruited into the study. In spite of the 70% health insurance coverage IDegLira is still a relatively costly medicine in Hungary. Only those patients who accepted the additional expenses of the treatment were enrolled.The main exclusion criteria were type 1 diabetes, applying glucose‐lowering agents other than insulin or metformin during 90 days before BV, active cancer, anaemia (haemoglobin <100 g/L) and acute or chronic kidney disease with an estimated glomerular filtration rate < 30 ml/min/1.73 m